Therefore, it is likely that the haploblock has antiviral effects against HIV-1 in all individuals carrying the HLA-B*57:01 allele during the early stages of infection and it is not surprising to see a similar SNP distribution within the haploblock in both the control group and the elite controller group (Figure 2). The gene discussed is HLA-B; the disease is infection.